Search | Clinical Trials Finder

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: RO6889450, Placebo, Risperidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more

Conditions: Tobacco Use Disorder
Interventions: Nicotine patch; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Piscataway, New Jersey

Conditions: Acute Schizophrenia, Schizoaffective Disorder
Interventions: RP5063, placebo, aripiprazole; Drug
Lead sponsor: Reviva Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Lurasidone HCl; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 27
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 21 more

Conditions: Schizophrenia
Interventions: Cognitive Remediation; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Granada Hills, California • Orange, California • New Haven, Connecticut + 11 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Texting for Relapse Prevention (T4RP); Behavioral
Lead sponsor: Center for Innovative Public Health Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone, Olanzapine, Quetiapine, Aripiprazole; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Fazaclo; Drug
Lead sponsor: Manhattan Psychiatric Center; Other
Eligibility: 18 Years to 59 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: New York, New York

Conditions: Patient Noncompliance
Interventions: haloperidol decanoate, haloperidol, Customized Adherence Enhancement; Drug · Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • National City, California • San Diego, California + 6 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: olanzapine, risperidone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Ziprasidone; Drug
Lead sponsor: Manhattan Psychiatric Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Bryant, Arkansas • Chino, California • Fountain Valley, California + 18 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia
Interventions: Aripiprazole, Ziprasidone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 41
States / cities: Anaheim, California • Cerritos, California • Culver City, California + 33 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 48
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: armodafinil (Nuvigil), placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperdal® Consta®, LY03004; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Orange County, California • Austin, Texas

Conditions: Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 23
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 20 more

Conditions: Schizophrenia
Interventions: NSA-789, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Bifeprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Orange, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Lurasidone HCl, Risperidone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more

Search by objective public record fields.

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

Texting for Relapse Prevention

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia